BRL 50481 Chemical Properties

Melting point:

65-67°C

Boiling point:

391.1±52.0 °C(Predicted)

Density 

1.334±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: 12 mg/mL

form 

solid

pka

-5?+-.0.70(Predicted)

color 

white

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

Safety Information

WGK Germany 

3

HS Code 

2935.90.9500

MSDS

• Language:English Provider:SigmaAldrich

BRL 50481 Usage And Synthesis

Description

BRL-50481 (433695-36-4) is a potent and selective inhibitor of phosphodiesterase-7 (PDE7), Ki=180 nM.1?Induces apoptosis in chronic lymphocytic leukemia cells which express PDE7B.2?BRL-50481 increases mineralization in osteoblasts differentiated from hMSC.3?Cell permeable.

Chemical Properties

Off-White Solid

Uses

A PDE7 inhibitor that has acceptable selectivity for in vivo studies

Definition

ChEBI: BRL-50481 is a C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM). It has a role as an EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor, a geroprotector and a bone density conservation agent. It is a sulfonamide, a C-nitro compound and a member of toluenes.

Biological Activity

Selective, substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (K i = 180 nM). Displays > 200-fold selectivity over PDE1B, PDE1C, PDE2, PDE3, PDE4A4 and PDE5.

Biochem/physiol Actions

BRL 50481 is a potent and selective PDE7 inhibitor (IC50 = 260 nM).

storage

Store at +4°C

References

1) Smith et al. (2004), Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes; Mol. Pharmacol., 66 1679 2) Zhang et al. (2008), Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia; Proc. Natl. Acad. Sci. USA 105 19532 3) Pekkinen et al. (2008), Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts; Bone 43 84

BRL 50481(433695-36-4)Related Product Information

• ZARDAVERINE
• RO 20-1724
• S- (+)-Rolipram
• ETAZOLATE
• Vinpocetine
• ZAPRINAST
• ROLIPRAM
• Cilostazol
• (4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE
• CILOSTAMIDE
• EHNA HYDROCHLORIDE
• 4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE
• BRL 50481
• 1-(2-METHYL-5-NITRO-BENZENESULFONYL)-PIPERIDINE-4-CARBOXYLIC ACID
• 1-[(2-METHYL-5-NITROPHENYL)SULFONYL]PIPERIDINE-2-CARBOXYLIC ACID
• TIMTEC-BB SBB001165
• 4-[4-[(2-METHYL-5-NITROPHENYL)SULFONYL]PIPERAZIN-1-YL]-4-OXOBUTANOIC ACID
• 1-[(2-METHYL-5-NITROPHENYL)SULFONYL]PIPERAZINE